Market Report, 124 Pages
Just Released — September 2021
A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. Contract development and manufacturing organizations (CDMOs) are similar, in that they offer services that include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies.
This 124-page market brief analyzes the scope of the manufacturing services currently required by the global cell and gene therapy (CGT) industry. It explores critical facility shortages impacting the industry, as well as the swell of funding flowing into the industry that is propelling unprecedented growth.
Contract Manufacturing for Cell and Gene Therapies
In addition to industry giants that include Lonza, Catalent, WuXi Advanced Therapies, Minaris Regenerative Medicine, and others, there are specialty CDMOs serving the CGT marketplace. For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. metres of GMP and GMP-compliant facilities for the production of ATMP’s, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.
There have also been enormous M&A deals within the cell and gene therapy CDMO sector. For example, industry behemoth Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7 billion, while Catalent acquired Paragon Bioservices for an impressive $1.2 billion and MaSTherCell for $315 million.
Similarly, Hitachi Chemical Advanced Therapeutics Solutions (HCATS), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. Regenerative Medicine now operate under the joint name of Minaris Regenerative Medicine. Of course, Charles River Laboratories (CRL) acquired Cognate BioServices for a hefty price tag of $875 million.
Funding the Cell and Gene Therapy Boom
The rapid ascension of cell and gene therapies (CGT) has created a crucial turning point in the history of modern medicine. Not only have new therapies such as CAR-T produced a shift towards highly individualized medicine and a powerful new front in the war against cancer, but the rapidity of change within the CGT sector has taken the world by storm.
By 2025, the FDA has indicated that it will be reviewing an estimated 10 to 20 CGTs per year, while the European Medicines Agency (EMA), has estimated that it will soon be approving as many as a dozen such therapies per year.
This 124-page market brief reveals critical activities within the cell and gene therapy sector, with a focus on three key areas:
- Expansions of Manufacturing Capacity
- Mergers & Acquisitions (M&A)
- Financing Events
With the hard-earned marketing approvals gained by cell and gene therapy companies in recent years, biopharmaceutical companies have substantially increased their interest in the CGT sector. Some biopharma companies are resorting to increasing their manufacturing capacity by investing in expansion and new facilities, while others are partnering with third-party contract manufacturing organizations to outsource this work.
With the future in mind, contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are also investing heavily in expanding their manufacturing capacity to be able to take on new clients and larger, later-stage projects as the market expands.
Currently, the cell and gene therapy field is currently on track for a massive capacity shortage. In particular, there is likely to be a shortage of manufacturing capacity at the commercial scale. Although approximately 90% of cell and gene therapy developers would prefer to use CMOs, related CMO capacity is not available within the industry.
Moreover, the lead time for CMOs to begin cell and gene therapy projects averages over 18 months. Thus, CGT developers are often forced to expand their in-house capacity. While CMOs are heavily investing into the expansion of cell and gene therapy manufacturing capabilities as well, these large-scale build-outs can often take years.
This global strategic report reveals:
- All known M&A deals recently executed within the CGT industry
- All known CMO & CDMO expansions by companies serving the CGT industry
- All known financing events executed within the CGT industry, including:
- Financing rounds
- Venture capital events
- Strategic and corporate partnerships
- Follow-on public offerings
- Profiles of all known competitors specializing in cell and gene therapy CMO and CDMO services (73 worldwide)
- A market size determination for the “Global Market for Cell and Gene Therapy (CGT) Manufacturing” with future forecasts through 2027
This 124-page global strategic report will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Outcompete your competition
- Implement an informed and advantageous business strategy in 2021
In compiling this report, BioInformant’s analysts leveraged nearly a decade of historical data on the cell and gene therapy manufacturing industry. In addition to conducting extensive research, our analysts interviewed industry leaders to identify emerging trends and market forces.
This report is tailed to the strategic needs of cell and gene therapy (CGT) companies, as well as the CMOs and CDMOs who are handling third-party manufacturing services for these clients.
With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.